Drugs / autologous NK cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05909098 | Jul 2023 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Xiangyang No.1 People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07375563 | Nov 2025 → Dec 2026 expected | ganglioneuroblastoma, neuroblastoma | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous NK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07375563 ↗ |
| Modality | Cell therapy | “autologous NK cells” NCT05909098 ↗ |